Date Title Description PDF
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
22 Feb 2022 On buy-back programmes ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.     Download
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download

Pages

Date Title Description PDF
12 Mar 2024 On business and financial situation ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies Download
08 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 March and 7 March 2024 Download
07 Mar 2024 On corporate transactions ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives  Download
01 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 23 February and 29 February 2024 Download
27 Feb 2024 Annual Corporate Governance Report ROVI releases the 2023 Annual Corporate Governance Report Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages